4 results match your criteria: "Ankara City Hospital Neurology Clinic[Affiliation]"
Erratum: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Noro Psikiyatr Ars
May 2023
Ondokuz Mayıs University, Faculty of Arts and Sciences, Department of Statistics, Samsun, Turkey.
[This corrects the article on p. 23 in vol. 60, PMID: 36911568.
View Article and Find Full Text PDFClinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Noro Psikiyatr Ars
January 2023
Ondokuz Mayıs University, Faculty of Arts and Sciences, Department of Statistics, Samsun, Turkey.
Introduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of the first generic fingolimod active ingredient treatment in different centers across Turkey.
Method: The first generic fingolimod efficacy and safety data of patients followed-up in 29 different clinical multiple sclerosis units in Turkey were analyzed retrospectively.
Psychoradiological evaluation of PLA2G6 gene mutations: Adult-onset dystonia-parkinsonism case report.
Parkinsonism Relat Disord
October 2022
Ankara City Hospital Neurology Clinic, Ankara, Turkey.
Article Synopsis
- The study investigates genetic counseling and clinical features of Turkish Huntington's disease (HD) patients since 2018, evaluating 141 individuals for symptoms and genetics.
- Among 84 participants who received counseling, 42% were genetically confirmed to have HD, with a mean onset age of 42.4 years; chorea was the most common initial symptom.
- Higher CAG repeat numbers correlated with earlier onset and more severe motor symptoms, indicating that paternal inheritance is linked to more severe disease traits, highlighting the need for collaborative management strategies in HD care.